Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GLS-010 + chemotherapy + bevacizumab
- Development stage
- Unknown
- Lead developer
- Guangzhou Gloria Biosciences
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
This is a **combination regimen** comprising GLS-010 (zimberelimab), a fully human anti-programmed death-1 (PD-1) monoclonal antibody, plus **chemotherapy** (the specific agents are not specified here), and **bevacizumab**, an anti-vascular endothelial growth factor (VEGF) monoclonal antibody. - **GLS-010 (zimberelimab)** blocks the interaction between PD-1 and its ligands (PD-L1/2), restoring T-cell activation and thereby exerting anti-tumor immune effects. - **Bevacizumab** binds to VEGF-A, inhibiting angiogenesis, starving tumors of blood supply. - **Chemotherapy** agents induce direct cytotoxicity against tumor cells, though the precise mechanisms depend on the specific agents used in the regimen. This combination targets **tumor immune evasion**, **tumor vascularization**, and **direct malignant cell cytotoxicity**.
- Brand names
- zimberelimab
- Other names
- zimberelimab + chemotherapy + bevacizumab
02
Targets
VEGFA (Vascular endothelial growth factor A)PDCD1 (Programmed cell death protein 1 receptor)
Beyond the preview
Go deeper on GLS-010 + chemotherapy + bevacizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GLS-010 + chemotherapy + bevacizumab.